Business Wire

Kymeta Appoints New Sales Executives in Move to Build Global Sales Force

Jaa

Kymeta—the communications company making good on the promise of global, mobile connectivity—today announced the appointment of Rash Jhanjee to Vice President of Sales, EMEA (Europe, Middle East, and Africa) & Indian Subcontinent, Paul Mattear to Vice President of Sales and Business Development, and Scott Glass to Sales Director.

Kymeta recognizes the appointment of Mattear, Jhanjee and Glass as a critical move that will support the global growth and accessibility of Kymeta solutions across multiple markets. Kymeta’s focus on its global sales force will help the company serve both commercial and government customers.

Jhanjee—who joined Kymeta in August 2018—brings more than 20 years of experience in global strategic business development and sales with a specific emphasis on EMEA and Asia. Having previously held EMEA sales leadership positions with Loral Cyberstar, Stratos, VT iDirect, O3B Networks, Intelsat Africa Limited, and Arabsat, Jhanjee will focus on development and support for Kymeta’s EMEA and Indian Subcontinent customers. In one of Jhanjee’s recent roles with Inmarsat, he was responsible for market development of the Global Xpress program across various mobility verticals. Jhanjee holds academic credentials in Business Information Systems from the University of Portsmouth.

Mattear—who joined Kymeta in June 2018— brings over 27 years of experience in government and commercial satellite communications. Mattear served 22 years in the United States Marine Corps (USMC), where he held senior command positions and culminated his carrier at the White House Communications Agency. Prior to Kymeta, Mattear held senior leadership and management positions at Intelsat (North American broadband and mobility) and Intelsat General (Government Network Solutions), where he created satellite network communications solutions and business development opportunities for commercial and government customers. Mattear holds an MBA in Business and an MS (Master of Science) in Telecommunications Systems from the University of Maryland University College. He also holds an MMS (Master of Military Studies) from the Marine Corps University.

Glass—who joined Kymeta in June 2018—brings nearly 30 years of experience in sales and business development for network solutions. He has held senior positions at several notable companies including NetApp, Nokia, Foundry Networks (Brocade), and VT iDirect. Most recently, Glass provided sales leadership in networking solutions for remote location, business continuity, mobility and cellular backhaul for VT iDirect commercial maritime, energy, and service provider customers. Glass holds a bachelor’s degree in Computer Applications from the University of Houston, Clear Lake.

“The addition of Rash, Paul, and Scott to the Kymeta team comes at a pivotal time in our growth,” said David Harrower, Senior Vice President, Global Sales, Kymeta, “We are focused on developing a global sales-driven organization, and with these appointments, we are building the sales force required to support our commercial and government customers across all regions. This team will allow us to maximize every opportunity and enable Kymeta solutions for new markets.”

About Kymeta

The world’s demand for ubiquitous mobile connectivity is irrefutable. A global, mobile network is the answer to connecting people and places that have never been connected before.

Kymeta is making seamless, always-connected mobile communications possible with a unique hybrid approach that enables satellite and cellular networks to deliver a single, global, mobile network. End-to-end mobile communications are delivered with Kymeta KĀLO™ connectivity services, and the world’s first and only electronically-steered, flat-panel satellite terminal that goes places traditional satellite dishes cannot. The Kymeta KyWay™ terminal makes high-throughput, mobile communications possible in cars, trains, buses, trucks, boats, and much more.

If it moves, Kymeta keeps it connected.

For more information, visit kymetacorp.com and KALO.net.

Contact information

Business Inquiries for Kymeta:
Sam Christensen
Marketing
Kymeta Corporation
+1 425.658.8703
schristensen@kymetacorp.com
or
Media Inquiries for Kymeta:
Amy Oliver
PR/Content Manager
The Summit Group
+1 801.990.1185
aoliver@summitslc.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 15:00:00 EETTiedote

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 14:30:00 EETTiedote

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 13:45:00 EETTiedote

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 13:00:00 EETTiedote

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 13:00:00 EETTiedote

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr

SmartStream Partners with Cassini Systems to Help Firms Meet Uncleared Initial Margin Obligations20.3.2019 12:00:00 EETTiedote

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced its partnership with Cassini Systems, the leading provider of pre and post trade margin analytics for buy side derivatives trading, to help financial institutions comply with BCBS-IOSCO margin requirements for uncleared OTC derivatives. BCBS-IOSCO defines rules for margin requirements on Uncleared Over-the-Counter (OTC) derivatives known as Uncleared Margin Rules (UMR). ISDA has developed a Standard Initial Margin Model (SIMM) that can be used by market participants to provide a transparent and standardised margin methodology of bi-lateral trades. The roll out of UMR rules has now reached the buy side with phase 4 firms coming into scope in September 2019, and phase 5 firms in September 2020. SmartStream’s TLM Collateral Management provides firms with automated data management to reduce operational risks associated with collateral management. This partnership will integra

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme